Persistent cognitive impairment associated with cerebrospinal fluid anti-SARS-CoV-2 antibodies six months after mild COVID-19

Abstract

Neurological long-term sequelae are increasingly considered an important challenge in the recent COVID-19 pandemic. However, most evidence for neurological symptoms after SARS-CoV-2 infection and central nervous system invasion of the virus stems from individuals severely affected in the acute phase of the disease. Here, we report long-lasting cognitive impairment along with persistent cerebrospinal fluid anti-SARS-CoV-2 antibodies in a female patient with unremarkable standard examination 6 months after mild COVID-19, supporting the implementation of neuropsychological testing and specific cerebrospinal fluid investigation also in patients with a relatively mild acute disease phase.

OriginalspracheEnglisch
ZeitschriftNeurological research and practice
Jahrgang3
Ausgabenummer1
Seiten (von - bis)34
ISSN2524-3489
DOIs
PublikationsstatusVeröffentlicht - 21.06.2021

Strategische Forschungsbereiche und Zentren

  • Querschnittsbereich: Medizinische Genetik
  • Forschungsschwerpunkt: Gehirn, Hormone, Verhalten - Center for Brain, Behavior and Metabolism (CBBM)

DFG-Fachsystematik

  • 2.23-07 Klinische Neurologie, Neurochirurgie und Neuroradiologie
  • 2.22-13 Pneumologie, Thoraxchirurgie
  • 2.21-05 Immunologie
  • 2.21-04 Virologie

Coronavirus-Bezug

  • Forschung zu SARS-CoV-2 / COVID-19

Fingerprint

Untersuchen Sie die Forschungsthemen von „Persistent cognitive impairment associated with cerebrospinal fluid anti-SARS-CoV-2 antibodies six months after mild COVID-19“. Zusammen bilden sie einen einzigartigen Fingerprint.

Zitieren